We exploit metal coordination and organometallic chemistry principles to design novel potent switchable bio-catalytic metallodrugs. These allow us to use amplified chemical reactivity in a controlled manner to modulate the cancerous cell machinery at the molecular level.
Our research seeks to exploit the physico-chemical features of the tumour (both intracellular and in the microenvironment) - resulting from their distinct metabolism, today known as the Warburg effect - for controlled drug activation (pro-drug approach).
Our main goal is to produce new metallo-organic drugs that can exert bio-catalytic activity inside human cancer cells. This - amplified through catalysis - effect on cells will aim to break their finely tuned redox and pH homeostasis in order to control cancer proliferation and stop invasion.
In addition, we take advantage on recent developments in nanomedicine to load our metallodrugs to a number of nano-systems which provide a variety of advantages, such as target cell accumulation. Finally, a fundamental aspect of our research is to describe the chemical interactions of our metallodrugs with the intracellular components at the nanoscale.